

# Contents

<i>Preface to the Fourth Edition</i>	<i>vii</i>
<i>Preface to the First Edition</i>	<i>ix</i>
<i>List of Contributors</i>	<i>xi</i>
<i>Long and Short Cases</i>	<i>xxi</i>

## SECTION 2

<b>21. Morphea and Lichen Sclerosus</b>	<b>687</b>	Epidermal Nevus Syndrome	766
Morphea	687	Inflammatory Linear Verrucous Epidermal Nevus (ILVEN)	767
Lichen Sclerosus (LS) and Balanitis Xerotica Obliterans	703	Nevus Sebaceous of Jadassohn	769
<b>22. Nail Disorders</b>	<b>709</b>	Comedo Nevus	771
Trachyonychia	709	Becker Nevus and Segmental Odonto-maxillary Dysplasia	773
Onychomycosis	712	Nevus Spilus	775
Nail Psoriasis	718	Linear and Whorled Nevoid Hyperpigmentation (LWNH)	777
Nail Lichen Planus	725	Nevus Depigmentosus	778
Melanonychia Striata	728	Nevus Anemicus	779
Miscellaneous Disorders	730	Congenital Melanocytic Nevi	780
<b>23. Necrobiotic Disorders</b>	<b>734</b>	Halo Nevus	783
Granuloma Annulare [GA]	734	Connective Tissue Nevus	785
Annular Elastolytic Giant Cell Granuloma (AEGCG), Actinic Granuloma of O'Brien, and Atypical Facial NLD	738	Heterotrimeric Guanine Nucleotide-Binding Protein (G-protein) Mosaic Disorders	786
Interstitial Granulomatous Dermatitis and Arthritis (IGDA) and Palisaded Neutrophilic Granulomatous Dermatitis (PNGD)	739	Porokeratotic Eccrine Ostial and Dermal Duct Nevus (PEODDN)	787
Necrobiosis Lipoidica	740	<b>26. Panniculitis</b>	<b>789</b>
<b>24. Neutrophilic Dermatoses</b>	<b>744</b>	Classification	789
Sweet Syndrome	744	Erythema Nodosum	790
Pyoderma Gangrenosum (PG)	749	<b>27. Perforating Dermatoses</b>	<b>793</b>
Behçet Disease	754	Acquired Perforating Dermatoses	793
Amicrobial Pustulosis (of the Skin Folds)	757	<b>28. Pigmentary Disorders</b>	<b>799</b>
<b>25. Nevi</b>	<b>760</b>	Pigmentary Demarcation Lines	799
Congenital Epidermal Nevi (CEN)	762	Acquired Disorders of Hyperpigmentation	801
Keratinocytic Verrucous Epidermal Nevus (VEN)	765		

- Facial Melanosis 801  
 Melasma 801  
 Riehl's Melanosis/Pigmented Contact Dermatitis/Photocontact Facial Melanosis 806  
 Lichen Planus Pigmentosus (LPP) 809  
 Erythema Dyschromicum Perstans (EDP) and Ashy Dermatitis (AD) 811  
 Idiopathic Eruptive Macular Hyperpigmentation 812  
 Lentiginosis (Acquired Causes) 813  
 Genetic Hyperpigmentary Disorders 815  
 Lentiginoses (Inherited Causes) 815  
 Incontinentia Pigmenti (IP) 815  
 Linear and Whorled Nevoid Hypermelanosis (LWNH) 819  
 Nevus of Ota (Naevus Fuscocaeruleus Ophthalmomaxillaris) and Nevus of Ito (Naevus Fuscocaeruleus Acromiodeltoideus) 821  
 Disorders of Hypopigmentation 826  
 Acquired Disorders of Hypopigmentation 828  
 Vitiligo 828  
 Halo Nevus 836  
 Idiopathic Guttate Hypomelanosis 837  
 Punctate Leukoderma 839  
 Progressive Macular Hypomelanosis 839  
 Chemical Vitiligo/Contact Leukoderma 840  
 Genetic Disorders of Hypopigmentation 842  
 Hypomelanosis of Ito (Linear and Block-like Hypo- and Hyperpigmentation) 842  
 Albinism 844  
 Piebaldism 847  
 Waardenburg Syndrome 848  
 Reticulate Pigmentary Disorders and Dyschromatosis 849
- 29. Pityriasis Rubra Pilaris 859**  
 Epidemiology 859  
 Etiopathogenesis 859  
 Clinical Features 859  
 Investigations 862
- 30. Psoriasis 864**  
 Types of Psoriasis 864  
 Plaque Psoriasis 864  
 Pustular Psoriasis 880  
 Generalized Pustular Psoriasis 880  
 Localized Pustular Psoriasis 884  
 Psoriatic Arthritis (PsA) 886
- 31. Reactive Arthritis (Reiter's Disease) 890**  
 Epidemiology 890  
 Etiopathogenesis 890  
 Clinical Features 891  
 Investigations 896  
 Treatment 896
- 32. Sarcoidosis 898**  
 Pathogenesis 898  
 Clinical Features 899  
 Histopathology 901  
 Differential Diagnosis 901  
 Investigations 902  
 Treatment 902
- 33. Sexually Transmitted Diseases 907**  
 Approach to a Patient with STD 907  
 Approach to Genital Ulcer Disease 911  
 Genital Ulcer Disease 915  
 Genital Herpes 916  
 Syphilis 932  
 Donovanosis (Granuloma Inguinale/Granuloma Venereum/Ulcerating Granuloma of Pudenda) 961  
 Inguinal Swelling 964  
 Chancroid 964  
 Lymphogranuloma Venereum (Tropical/Climatic Bubo, Durand-Nicolas-Favre Disease) 969  
 Urethritis 973  
 Approach to a Case of Urethritis 975  
 Gonococcal Urethritis 976  
 Nongonococcal Urethritis 990  
 Chlamydia Trachomatis 990  
 Persistent and Recurrent NGU 995  
 Anogenital Warts 998

Vaginal Discharge, Cervicitis, and PID	1010	Kaposiform Hemangioendothelioma (KHE)	1065
Approach to a Patient of Vaginal Discharge	1010	Kapsoi Sarcoma	1066
Syndromic Approach	1024	Malignant Tumors	1069
Sexual Assault and STIs	1031	Basal Cell Carcinoma (BCC)	1069
<b>34. Tumors: Benign Appendageal, Malignant and Premalignant Tumors</b>	<b>1041</b>	Squamous Cell Carcinoma (SCC)	1076
Appendageal Tumors	1041	Malignant Melanoma	1083
Syringoma	1046	Cutaneous Lymphomas	1090
Trichoepithelioma	1047	Mycosis Fungoides	1091
Pilomatricoma	1049	Sézary Syndrome	1098
Cutaneous Leiomyomas	1052	Other T Cell Lymphomas	1100
Cutaneous Cysts	1054	B Cell Lymphoma	1105
Sebaceous Hyperplasia	1057	Premalignant Tumors	1111
Paget's Disease of the Nipple	1057	Actinic Keratoses (AK)	1111
Extramammary Paget's Disease (EMPD)	1059	Disseminated Superficial Actinic Porokeratosis (DSAP)	1113
Vascular Tumors	1060	Erythroplasia of Queyrat	1115
Glomeruloid Hemangioma	1062	Bowen's Disease (BD)	1117
Tufted Hemangioma	1064	<b>35. Xanthomas and Hyperlipoproteinemia</b>	<b>1122</b>
		Overview of Lipoprotein Transport	1122
		Clinical Types, Pathogenesis and Treatment of Hyperlipoproteinemias	1123
<b>SECTION 3</b>			
<b>36. Fundamentals of Dermatology</b>	<b>1133</b>	Pathophysiology	1175
Structure and Function of Skin	1133	Clinical Classification	1175
Epidermis	1134	Cutaneous Manifestations	1178
Basement Membrane Zone	1141	Diagnosis of HIV	1186
Cells	1143	Treatment	1187
Hair	1145	HIV Risk and PEP	1189
Sebaceous Glands	1148	Post-exposure Prophylaxis (PEP)	1190
Eccrine Glands	1148	<b>39. Vasculitis</b>	<b>1192</b>
Apocrine Glands	1149	Immune Complex-Mediated Small-Vessel Vasculitides	1195
Nerves and Receptors of the Skin	1149	Granuloma Faciale	1202
<b>37. Immunodermatology</b>	<b>1151</b>	ANCA-associated Vasculitis	1203
Innate Response	1151	Medium Vessel Vasculitis	1206
Adaptive Immunity	1154	Large Vessel Vasculitis	1209
Immunology of the Skin	1170	<b>40. Dermoscopy Basics and Applied</b>	<b>1213</b>
Immunological Response Patterns of Inflammatory Skin Diseases	1172	Papulosquamous Disorders	1214
<b>38. HIV: Skin Manifestations and Management</b>	<b>1175</b>	Granulomatous Disorders	1223
Epidemiology	1175		

- Disorders of Pigmentation 1228
- Infective Disorders 1234
- Malignant and Pre-malignant
  - Dermatoses 1238
- Miscellaneous 1242
- 41. Dermatopathology 1249**
  - Histological Features 1249
  - Inflammatory Patterns 1257
  - Image Bank 1263
- 42. Systemic Drugs in Dermatology 1280**
  - Acitretin 1280
  - Antiandrogens 1285
  - 5-Alpha Reductase Inhibitors 1285
  - Androgen Receptor Blocker 1287
  - Antimalarials 1290
  - Hydroxychloroquine Sulfate 1290
  - Antifungal Drugs 1293
    - Classification 1293
    - Itraconazole 1296
    - Fluconazole 1301
    - Terbinafine 1302
    - Griseofulvin 1303
    - Apremilast 1304
    - Azathioprine 1305
    - Biologics for Psoriasis 1308
    - Basics of Immunology 1308
    - When to give Biologics 1308
    - Comparison of Biologics 1311
    - How to Manage Failure of
      - Biologic Therapy 1311
    - Workup 1311
    - Special Scenarios 1312
    - Biologics Overview and Efficacy 1314
    - Anti-TNF- $\alpha$  Agents 1314
    - Interleukin-17 Antagonists 1317
    - Interleukin-12/23 Biologicals 1318
    - B Cell Targeted Therapy 1321
    - Cyclosporine 1328
    - Colchicine 1333
    - Corticosteroids 1335
    - Cyclophosphamide 1344
    - Dapsone 1349
    - Isotretinoin 1352
    - Intravenous Immunoglobulin 1357
    - Ivermectin 1360
    - Janus Kinase Inhibitors 1362
      - Cytokine-JAK Axis 1364
    - Monitoring and Screening 1369
    - Tofacitinib Citrate 1371
    - Methotrexate 1373
    - Mycophenolate Mofetil 1379
    - Propranolol 1381
    - Photochemotherapy/Psoralens 1383
    - Saturated Solution of Potassium
      - Iodide (SSKI) 1387
    - Thalidomide (Immunomodulatory
      - Imide Drugs/ImiDs) 1389
    - Tetracycline 1392
    - Minocycline 1392
  - 43. Dermatosurgery Instruments 1404**
    - Preparatory Instruments 1404
    - Cutting and Dissecting Instruments 1406
    - Holding Instruments 1408
    - Retractors and Exposing Instruments 1409
    - Wound-Closing Instruments
      - and Materials 1410
    - Instruments Used for Special Surgeries 1417
  - 44. Common Radiological Images in Dermatology 1427**
    - Infections 1427
    - Inflammatory and Autoimmune
      - Conditions 1434
    - Autoimmune Connective Tissue
      - Diseases 1437
    - Gout 1438
    - Genodermatoses and
      - Syndromic Associations 1439
    - Histiocytoses 1440
    - Vitamin and Mineral Deficiency 1441
    - Therapy Related Bone Changes 1442
  - 45. Why Dermatology and What to do Next? Matters and Musings 1443**
    - Why Spend Money on a Book? 1443
    - What One Must and Must Not
      - Do in MD Training? 1444

Talks, Webinars Beyond Books?	1445	Shall I Join Practice or Teaching?	1451
What is “Good” Research Work? And can a Postgraduate Resident do such Work?	1446	What will Happen in Life, will I be Able to Survive the Competition?	1451
Cosmetology, Quackery, Choices we Make!	1447	Time to Stop and Look Elsewhere?	1451
Should Practice be Like a Business Model?	1450	How much Money is Good Enough? Or is it Really Good Enough?	1452
		What is the Purpose of my Life?	1453

# Contents

<i>Preface to the Fourth Edition</i>	<i>vii</i>
<i>Preface to the First Edition</i>	<i>ix</i>
<i>List of Contributors</i>	<i>xi</i>
<i>Long and Short Cases</i>	<i>xix</i>

## SECTION 1

<b>1. Acne Vulgaris</b>	<b>3</b>	Diagnosis	69
Etiopathogenesis	3	Treatment	70
Clinical Variants of Acne	9		
Investigations for Acne	12		
Treatment of Acne	14		
Acne Scars	23		
<b>2. (Acne) Rosacea</b>	<b>32</b>		
Diagnosis	35		
Treatment	36		
<b>3. Adverse Drug Reactions</b>	<b>38</b>		
Classification	38		
Pathogenesis	39		
Erythema Multiforme	41		
Severe Cutaneous Adverse Reactions	43		
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis	43		
Acute Generalized Exanthematous Pustulosis (AGEP)	51		
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Drug-induced Hypersensitivity Syndrome (DIHS)	52		
Miscellaneous Drug Eruptions	56		
Anticancer Therapies and their Associated Dermatologic Adverse Events	58		
Targeted Therapy and their ADRs	61		
<b>4. Amyloidosis</b>	<b>65</b>		
Definition and Types	65		
Types of Cutaneous Amyloidosis	65		
		<b>5. Annular (Figurate) Erythemas</b>	<b>73</b>
		Erythema Annulare Centrifugum (EAC)	73
		Erythema Marginatum (Rheumaticum)	73
		Erythema (Chronicum) Migrans (ECM)	73
		Erythema Gyratum Repens (EGR)	73
		Erythema Multiforme (EM)	76
		Annular Erythema of Infancy (AEI)	77
		Necrolytic Migratory Erythema (NME)	78
		<b>6. Atopic Dermatitis</b>	<b>80</b>
		Pathophysiology	80
		Clinical Features of AD	83
		Management	85
		Management Algorithm for Atopic Dermatitis	92
		<b>7. Autoimmune Bullous Diseases</b>	<b>98</b>
		Pemphigus	98
		Pemphigus Vulgaris (PV)	102
		Pemphigus Vegetans	107
		Pemphigus Foliaceus (PF)	108
		Pemphigus Erythematosus (PE)	109
		Endemic Pemphigus Foliaceus	110
		Pemphigus Herpetiformis	110
		Paraneoplastic Pemphigus/Paraneoplastic Autoimmune Multi-Organ Syndrome (PAMS)	110
		IgA Pemphigus	112
		Induced Pemphigus	113

Treatment of Pemphigus	118		
Subepidermal Immunobullous Diseases	126		
Bullous Pemphigoid	126		
Mucous Membrane Pemphigoid	138		
Linear IgA Disease and CBDC	143		
Anti-p200 Pemphigoid	145		
Epidermolysis Bullosa Acquisita	146		
Pemphigoid Gestationis (Herpes Gestationis)	148		
Bullous SLE	149		
Dermatitis Herpetiformis (Duhring-Brocq Disease)	151		
<b>8. Autoimmune Connective Tissue Diseases</b>		<b>159</b>	
ANA and its Significance	159		
Measurement of ANA	159		
Disease Specific ANA	163		
Interpretation of ANA	164		
Lupus Erythematosus	166		
Systemic Lupus Erythematosus	166		
Chronic Cutaneous LE (CCLE/DLE)	184		
Subacute Cutaneous LE (SCLE)	192		
Systemic Sclerosis	193		
Dermatomyositis and Idiopathic Inflammatory Myopathy (IIM)	213		
MCTD/Overlap Syndrome/Sharp Syndrome	226		
<b>9. Cutaneous Mosaicism</b>		<b>227</b>	
Introduction	227		
Classification	231		
Treatment	233		
<b>10. Dermatitis</b>		<b>235</b>	
Airborne Contact Dermatitis (ABCD)/ Aeroallergic Dermatitis	235		
I. Airborne Irritant Contact Dermatitis (ABICD)	238		
II. Airborne Allergic Contact Dermatitis (ABACD)	239		
III. Airborne Contact Urticaria	239		
Treatment of ABCD	240		
Phyto dermatitis	241		
Parthenium Dermatitis (PD)	242		
<b>11. Erythroderma</b>		<b>247</b>	
Clinical Features	249		
Neonatal Erythroderma	251		
Investigations	252		
Approach to Diagnosis	255		
Management	256		
<b>12. Follicular Disorders</b>		<b>259</b>	
Classification	259		
Keratosis Pilaris (KP)	259		
Lichen Spinulosus	264		
<b>13. Genetic Skin Disorders</b>		<b>269</b>	
Genetic Disorders of Collagen, Elastic and Dermal Matrix	269		
Ichthyosis	289		
Neurocutaneous/Hamartoneoplastic Syndromes	310		
Porphyria	323		
Palmoplantar Keratoderma	331		
Premature Aging Syndrome	340		
DNA Repair Disorders	347		
Dyskeratotic–Acantholytic Disorders	356		
Epidermolysis Bullosa	365		
Ectodermal Dysplasia	377		
<b>14. Hair Disorders</b>		<b>385</b>	
Non-cicatricial Alopecia	385		
Alopecia Areata	385		
Trichotillomania	397		
Newer Drugs Causing Alopecia	400		
TNF Inhibitors	400		
Dupilumab	400		
Cicatricial Alopecia	401		
Follicular Lichen Planus	403		
Pseudopelade of Brocq	409		
Central Centrifugal Cicatricial Alopecia (CCCA)	410		
Folliculitis Decalvans	411		
Hair Shaft Disorders	413		
<b>15. Hemangioma and Vascular Malformations</b>		<b>420</b>	
Hemangioma	420		
Congenital Hemangioma	430		
Vascular Malformations	432		

Venous Malformations	438		
Lymphatic Malformations	441		
Lymphedema	444		
Arteriovenous Malformations (AVMs)	444		
Other Vascular Disorders	446		
Angiokeratoma	446		
<b>16. Hidradenitis Suppurativa</b>	<b>450</b>		
Pathogenesis	451		
Clinical Features	452		
Severity Scoring	453		
Treatment	454		
<b>17. Infections</b>	<b>460</b>		
Bacterial Infections	460		
Corynebacterial Cutaneous Infections	468		
Cutaneous TB: Typical and Atypical	471		
Fungal Infections	498		
Superficial Mycoses	499		
Subcutaneous Mycoses	510		
Systemic Mycoses	533		
Viral Infections	535		
Cutaneous Leishmaniasis and Post-Kala-Azar Dermal Leishmaniasis (PKDL)	556		
Infestations	573		
Scabies	573		
<b>18. Leprosy</b>	<b>596</b>		
Pathogenesis	600		
Classification	603		
Clinical Features	606		
Leprosy Reactions	618		
Investigations	622		
Treatment	626		
Drug-resistant Leprosy	631		
Treatment of Reactions	632		
Relapse in Leprosy	635		
Disability and Nerve Testing	639		
<b>19. Lichen Planus and Lichenoid Disorders</b>	<b>655</b>		
Lichen Planus (LP)	655		
Lichen Planus Pigmentosus (LPP)	668		
Lichen Nitidus (LN)	669		
Lichen Striatus	670		
<b>20. Mastocytosis</b>	<b>672</b>		
Clinical Features of Cutaneous Mastocytosis	673		
Diagnosis of Systemic Mastocytosis	677		
Treatment	678		
<b>Index</b>	<b>681</b>		